Selenium-antibody conjugate
Patent Information
- Application Number
- JP2023552152
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-10
- Filing Date
- 2021-11-09
- Publication Date
- 2024-11-14
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing antibody-drug conjugates (ADCs) face challenges in site-specific conjugation methods that are inefficient, lack chemical compatibility with certain payloads, and result in variable drug-to-antibody ratios, complicating purification and mixture variability.
Development of ADCs with selenium-containing linkers that connect an antigen-binding domain and a payload, using a formula Z-(Gln-NH-L-Se-L1-R)n, where Z is the antigen-binding domain, Gln is glutamine, NH is the side chain of glutamine, L and L1 are linkers, R is the payload, and n is an integer from 1 to 10, enabling site-specific conjugation.
The selenium-containing linkers provide efficient, site-specific ADCs with improved purity and consistent drug-to-antibody ratios, enhancing therapeutic efficacy and diagnostic accuracy.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] Related Applications This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 112,044, filed November 10, 2020, the contents of which are incorporated herein by reference in their entirety.
[0002] Provided herein are antibody conjugates, including antibody drug conjugates (ADCs), that comprise a selenium-containing linker. [Background technology]
[0003] ADCs combine the power of antibody specificity with the ability to site-specifically target specific cell types or tissues with a payload. Research in this area has attracted significant interest and led to the sale of pharmaceutical products, including ADCETRIS® (brentuximab vedotin) and KADCYLA™ (ado-trastuzumab emtansine). Often, antibodies have been conjugated to payloads in a nonspecific manner, resulting in a mixture of ADCs that are difficult to purify, without the payload being conjugated to a defined location on the antibody. Furthermore, standard conjugation methods result in variability in the drug-to-antibody ratio (DAR), adding further complexity to the resulting ADC mixture.
[0004] More recently, processes for site-specific conjugation of antibodies to payloads have been developed. See, for example, Agarwal et al., Bioconjugate Chem. 2015, 26, 176-192. However, these processes have limitations, including lack of compatibility and / or chemical cross-reactivity with certain payloads. For example, Dennler et al. (Bioconjugate Chem. 2014, 25, 569-578) developed an SAc thiol linker (C6-SAc), but concluded that inefficient deacetylation of the intermediate thiol prevented the method from being completely successful.
[0005] Thus, there is a continuing need for efficient, site-specific methods for producing ADCs, and ADCs produced by such methods. Summary of the Invention
[0006] Provided herein is an ADC having a selenium-containing linker connecting the antigen-binding domain and the payload. In one embodiment, the antigen-binding domain is an antibody or an antigen-binding fragment thereof. In another embodiment, the payload is a therapeutic agent or an imaging agent. In another embodiment, the therapeutic agent is a cytotoxin. In another embodiment, the ADC provided herein has the following formula I:
[0007] Z-(Gln-NH-L-Se-L 1 -R) n
[0008] or a pharmaceutically acceptable salt thereof, wherein:
[0009] Z is an antigen-binding domain,
[0010] Gln is glutamine in the antigen-binding domain;
[0011] NH is the side chain NH of Gln,
[0012] L and L 1 are the same or different and each is a linker;
[0013] R is the payload,
[0014] N is an integer from 1 to 10.
[0015] In another embodiment, the ADCs provided herein are useful in methods of treatment or imaging or diagnostic methods. [Brief explanation of the drawings]
[0016] [Figure 1]FIG. 1 is a diagram of a process for synthesizing an ADC provided herein, wherein Z is an antibody, L is ethylene, L1 is a linker derived from mc-vc-PAB in one embodiment, and R is a payload, which in one embodiment is MMAE.
[0017] [Figure 2A] Mass spectrometry spectra of deglycosylated mAb1 (degly-mAb1), deglycosylated mAb1-Se (degly-mAb1-1 after reaction with selenocystamine and MTGase), deglycosylated mAb1-Se-MMAE (degly-mAb1-1-mc-vc-PAB-MMAE after reaction with mc-vc-PAB-MMAE), and a mock-control reaction of mAb1 with mc-vc-PAB-MMAE are shown. [Figure 2B] Mass spectrometry spectra of deglycosylated mAb1 (degly-mAb1), deglycosylated mAb1-Se (degly-mAb1-1 after reaction with selenocystamine and MTGase), deglycosylated mAb1-Se-MMAE (degly-mAb1-1-mc-vc-PAB-MMAE after reaction with mc-vc-PAB-MMAE), and a mock-control reaction of mAb1 with mc-vc-PAB-MMAE are shown.
[0018] [Figure 3] Mass spectrometry spectra of deglycosylated ISOmAb (degly-ISOmAb), deglycosylated ISOmAb-Se (degly-ISOmAb-1 after reaction with selenocystamine and MTGase), and deglycosylated ISOmAb-Se-MMAE (degly-ISOmAb-1-mc-vc-PAB-MMAE after reaction with mc-vc-PAB-MMAE) are shown.
[0019] [Figure 4] Figure 1 shows size-exclusion HPLC (SEC) of deglycosylated mAb1-Se-MMAE (degly-mAb1-1-mc-vc-PAB-MMAE) and deglycosylated ISOmAb-Se-MMAE (degly-ISOmAb-1-mc-vc-PAB-MMAE).
[0020] [Figure 5] 1 shows cell viability in HER+ (SKBR3) and HER2- (H1975) cell lines upon incubation with ADCs provided herein. DETAILED DESCRIPTION OF THE INVENTION
[0021] i.Definition To facilitate understanding of the disclosure set forth herein, several terms are defined below.
[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. All patents, applications, published applications and other publications are incorporated by reference in their entirety. In the event that there are multiple definitions for a term herein, those in this section prevail unless expressly stated otherwise.
[0023] The singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise.
[0024] As used herein, a "subject" is an animal, such as a mammal, including a human, such as a patient.
[0025] As used herein, biological activity refers to the in vivo activity or physiological response of a compound that occurs upon in vivo administration of the compound, composition, or other mixture. Thus, biological activity encompasses the therapeutic effects and pharmacokinetic behavior of such compounds, compositions, and mixtures. Biological activity can be observed in in vitro systems designed to test such activity.
[0026] As used herein, "antigen-binding domain" refers to any peptide, polypeptide, nucleic acid molecule, scaffold molecule, peptide display molecule, or polypeptide-containing construct that is capable of specifically binding to a particular antigen of interest. As used herein, "antigen-binding domain" includes antibodies and antigen-binding fragments of antibodies. All references herein to proteins, polypeptides, and protein fragments are intended to refer to the human version of the respective protein, polypeptide, or protein fragment, unless explicitly specified as being from a non-human species.
[0027] As used herein, the term "specifically binds" or the like refers to an antigen-binding domain that binds to an antigen with a dissociation constant (K D ) means that the antibody forms a complex with a specific antigen, characterized by the presence of a specific antibody, and does not bind to other unrelated antigens under typical test conditions.
[0028] As used herein, "unrelated antigens" are proteins, peptides, or polypeptides that share less than 95% amino acid identity with each other.
[0029] The term "antibody," as used herein, refers to any antigen-binding molecule or molecular complex that contains at least one complementarity-determining region (CDR) that specifically binds to or interacts with a particular antigen (e.g., human HER2). The term "antibody" includes immunoglobulin molecules that contain four polypeptide chains, two heavy (H) chains and two light (L) chains, inter-connected by disulfide bonds, as well as multimers thereof (e.g., IgM). Each heavy chain contains a heavy chain variable region (referred to herein as HCVR or V). H The heavy chain constant region comprises three domains: C H 1. C H 2, and C H Each light chain comprises a light chain variable region (referred to herein as LCVR or V L The light chain constant region comprises one domain (C L 1) VH and V L The region can be further subdivided into regions of hypervariability called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). H and V L is composed of three CDRs and four FRs arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0030] As used herein, the term "antigen-binding fragment" of an antibody means any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex.
[0031] As used herein, the term "human antibody" refers to an antibody having variable and constant regions derived from human germline immunoglobulin sequences. Nevertheless, human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), e.g., in the CDRs, and particularly in the CDR3. However, the term "human antibody," as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species (e.g., a mouse) have been grafted onto human framework sequences.
[0032] As used herein, the term "recombinant human antibody" means a fully human antibody that is prepared, expressed, created, or isolated by recombinant means, such as an antibody expressed using a recombinant expression vector transfected into a host cell (described further below), an antibody isolated from a recombinant combinatorial human antibody library (described further below), an antibody isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see, e.g., Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295), or an antibody prepared, expressed, generated, or isolated by any other means, including splicing of human immunoglobulin gene sequences into other DNA sequences.
[0033] As used herein in the context of amino acid sequences, the term "substantial identity" or "substantially identical" means that two amino acid sequences share at least 95%, 98%, or 99% sequence identity when optimally aligned, such as by the programs GAP or BESTFIT, using predefined gap weights.
[0034] As used herein, the term "surface plasmon resonance" refers to an optical phenomenon that allows for the analysis of interactions in real time by detection of changes in protein concentration within a biosensor matrix, for example, using a BIAcore™ system (Biacore Life Sciences division of GE Healthcare, Piscataway, NJ).
[0035] "K D The term "" as used herein refers to the equilibrium dissociation constant of a particular protein-protein interaction (e.g., an antibody-antigen interaction). Unless otherwise indicated, the K D Values are K determined by surface plasmon resonance assay at 25 °C. D Points to a value.
[0036] As used herein, pharmaceutically acceptable salts include, but are not limited to, amine salts such as N,N'-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N-benzylphenethylamine, 1-para-chlorobenzyl-2-pyrrolidin-1'-ylmethylbenzmidazole, diethylamine and other alkylamines, piperazine and tris(hydroxymethyl)aminomethane; alkali metal salts such as, but not limited to, sodium; alkaline earth metal salts such as, but not limited to, barium, calcium, and magnesium; transition metal salts such as, but not limited to, zinc; and inorganic salts such as, but not limited to, sodium hydrogen phosphate and disodium phosphate; and also mineral acid salts such as, but not limited to, hydrochloride and sulfate; and organic acid salts such as, but not limited to, acetate, lactate, malate, tartrate, citrate, ascorbate, succinate, butyrate, valerate, mesylate, and fumarate.
[0037] As used herein, treatment refers to any manner in which one or more symptoms of a disease or disorder are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein, such as use to treat tumors, including HER2-positive tumors, such as breast cancer.
[0038] As used herein, amelioration of symptoms of a particular disorder by administration of a particular compound or pharmaceutical composition refers to any relief, whether permanent or temporary, lasting or transient, that can result from or be associated with administration of the compound or pharmaceutical composition.
[0039] As used herein, IC 50 refers to the amount, concentration or dosage of a particular test compound that achieves 50% inhibition of a maximal response in an assay that measures such response.
[0040] Where moieties are specified by their conventional chemical formula written from left to right, they are equivalent and encompass the chemically identical moieties that result from writing the structure from right to left, e.g., -CH2O- is equivalent to -OCH2-.
[0041] The term "alkyl," by itself or as part of another substituent, means, unless otherwise stated, a straight-chain (i.e., unbranched) or branched-chain saturated hydrocarbon radical. The term "alkylene," by itself or as part of another substituent, means a divalent radical derived from alkyl. Typically, an alkyl (or alkylene) group has 1 to 24 carbon atoms, with groups having 10 or fewer carbon atoms. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having 6 or fewer carbon atoms. Examples of alkyl groups include, but are not limited to, homologs and isomers of, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, e.g., n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
[0042] The term "alkenyl," by itself or as part of another substituent, means, unless otherwise stated, a straight-chain (i.e., unbranched) or branched-chain hydrocarbon radical having one or more carbon-carbon double bonds. The term "alkenylene," by itself or as part of another substituent, means a divalent radical derived from alkenyl. Typically, an alkenyl (or alkenylene) group has 1 to 24 carbon atoms, with groups having 10 or fewer carbon atoms. A "lower alkenyl" or "lower alkenylene" is a shorter chain alkenyl or alkenylene group, generally having 6 or fewer carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl (i.e., ethenyl), 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), and higher homologs and isomers.
[0043] The term "alkynyl," by itself or as part of another substituent, unless otherwise stated, refers to an alkyl group having the specified number of carbon atoms (i.e., C1-C6). 10 means 1 to 10 carbons) divalent and polyvalent radicals. Examples of alkynyl groups include, but are not limited to, ethynyl, 1- and 3-propynyl, 3-butynyl, and higher homologs and isomers.
[0044] The terms "alkoxy," "alkylamino," and "alkylthio" (or thioalkoxy) are used in their conventional sense to refer to those alkyl groups attached to the remainder of the molecule through an oxygen atom, an amino group, or a sulfur atom, respectively.
[0045] The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a straight or branched chain hydrocarbon radical consisting of heteroatoms in the chain selected from the group consisting of O, N, P, Si, and S, where the nitrogen and sulfur atoms can be optionally oxidized, the nitrogen atom can have alkyl substituents to satisfy valence, and / or can be optionally quaternized. The heteroatom(s) O, N, P, Si, and S can be placed at any interior position of the heteroalkyl group. Examples include, but are not limited to, -CH-CH-O-CH, -CH-CH-NH-CH, -CH-CH-N(CH)-CH, -CH-S-CH-CH, -CH-CH-S(O)-CH, -CH-CH-S(O)-CH, -CH=CH-O-CH, -CH-CH=N-OCH, and -CH=CH-N(CH)-CH. Up to two heteroatoms may be consecutive, such as, for example, -CH-NH-OCH and -CH-O-Si(CH). Similarly, the term "heteroalkylene" by itself or as part of another substituent means a divalent radical derived from heteroalkyl, exemplified by, but not limited to, -CH-CH-S-CH-CH- and -CH-S-CH-CH-NH-CH-. For alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(O)R'- represents both -C(O)R'- and -R'C(O)-.
[0046] The terms "cycloalkyl" and "heterocycloalkyl," by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl," respectively, and include bicyclic, tricyclic, and bridged bicyclic groups. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. The terms "cycloalkylene" and "heterocycloalkylene," by themselves or as part of another substituent, mean a divalent radical derived from a cycloalkyl or heterocycloalkyl. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, norbornanyl, bicyclo(2.2.2)octanyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, 1- or 2-azabicyclo(2.2.2)octanyl, and the like.
[0047] The term "aryl," unless otherwise stated, means a polyvalent unsaturated aromatic hydrocarbon substituent which may be a single ring or multiple rings (in one embodiment, 1 to 3 rings), fused together or covalently linked. The term "heteroaryl" refers to an aryl group containing 1 to 4 heteroatoms selected from N, O, and S in the ring(s), wherein the nitrogen and sulfur atoms are optionally oxidized and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom. The terms "arylene" and "heteroarylene," by themselves or as part of another substituent, mean a divalent radical derived from an aryl or heteroaryl. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-
[0023] The term "heteroarylium" refers to a heteroaryl group in which one or more of the heteroatoms is positively charged.
[0048] Each of the above terms is meant to include both substituted and unsubstituted forms of the indicated radical. Non-limiting examples of substituent moieties for each type of radical are provided below.
[0049] Substituent portions of alkyl, heteroalkyl, alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl groups may, in one embodiment, be selected from deuterium, —OR′, ═O, ═NR′, ═N—OR′, —NR′R″, —SR′, halo, —SiR′R, in a number ranging from zero to the number of hydrogen atoms in such radical. In one embodiment, the substituent moieties of cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl groups are selected from substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, and substituted and unsubstituted alkynyl. In one embodiment, R', R", R'", and R"" are each independently hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted alkyl, alkoxy or thioalkoxy, or arylalkyl groups. When the compounds provided herein include more than one R group, for example, each of the R groups is independently selected as are each of the R', R", R'", and R'" groups when two or more of these groups are present. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, -NR'R" is meant to include, but not be limited to, 1-pyrrolidinyl and 4-morpholinyl.From the above discussion of substituent moieties, one of skill in the art will understand that the term "alkyl" is meant to include groups that contain carbon atoms bonded to groups other than hydrogen groups, such as haloalkyl (e.g., -CF and -CHCF) and acyl (e.g., -C(O)CH, -C(O)CF, -C(O)CHOCH, etc.).
[0050] Substituent moieties on aryl and heteroaryl groups, in one embodiment, include deuterium, halo, substituted and unsubstituted alkyl, substituted and unsubstituted alkenyl, and substituted and unsubstituted alkynyl, —OR′, —NR′R″, —SR′, —SiR′R″R″′, —OC(O)R′, —C(O)R′, —COR′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′—C(O)NR″R″′, —NR″C(O)R′, —NR—C(NR′R″R′”)═NR″″, —NR—C(NR′ R") = selected from NR'", -S(O)R', -S(O)R', -S(O)NR'R", -NRSOR', -CN and -NO, -R', -N, -CH(Ph), fluoro(C-C)alkoxy, and fluoro(C-C)alkyl, wherein R', R", R'" and R"", in one embodiment, are independently selected from hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted heteroalkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocycloalkyl, substituted and unsubstituted aryl, and substituted and unsubstituted heteroaryl. When a compound provided herein includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R'", and R'" groups when two or more of these groups are present.
[0051] Two of the substituent moieties on adjacent atoms of the aryl or heteroaryl ring are optionally represented by the formula -Q'-C(O)-(CRR') q Alternatively, two of the substituent moieties on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -A-(CH2)r A and B may be independently substituted with a substituent of -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O) 2-、 -S(O)NR'- or a single bond, where r is an integer from 1 to 4. One of the single bonds of the new ring thus formed may optionally be replaced with a double bond. Alternatively, two of the substituent moieties on adjacent atoms of the aryl or heteroaryl ring may optionally be a group of the formula -(CRR') s -X'-(CR''R''') d where s and d are independently integers from 0 to 3, and X' is -O-, -NR'-, -S-, -S(O)-, -S(O)2-, or -S(O)2NR'-. The substituent moieties R, R', R" and R" in one embodiment are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
[0052] The term "halo," by itself or as part of another substituent, means, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl" are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C1-C4)alkyl" is meant to include, but is not limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
[0053] The term "oxo" as used herein means an oxygen atom that is double bonded to a carbon atom.
[0054] As used herein, the term "heteroatom" or "ring heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
[0055] L and L provided herein 1Certain ADCs, including: have asymmetric carbon atoms (optical centers) or double bonds, and the racemates, diastereomers, tautomers, geometric isomers, and individual isomers are encompassed within the scope of this disclosure. The ADCs provided herein do not include those known in the art to be too unstable to synthesize and / or isolate.
[0056] II. ADCs for Use in Compositions and Methods In one embodiment, the compound of formula I:
[0057] Z-(Gln-NH-L-Se-L 1 -R) n
[0058] Provided herein is an ADC for use in the compositions and methods provided herein, having the formula:
[0059] Z is an antigen-binding domain,
[0060] Gln is glutamine in the antigen-binding domain;
[0061] NH is the side chain NH of Gln,
[0062] L and L 1 are the same or different and each is a linker;
[0063] R is the payload,
[0064] N is an integer from 1 to 8.
[0065] In another embodiment, n is an integer from 1 to 6. In another embodiment, n is an integer from 1 to 4. In another embodiment, n is 2 or 4. In another embodiment, n is 2.
[0066] A. Antigen-binding domain Z In one embodiment, Z of the antigen-binding domain for use in the ADCs provided herein, i.e., Formula I, comprises any molecule that specifically interacts with a particular antigen. In certain embodiments, Z is an antibody or an antigen-binding fragment of an antibody. In other embodiments, Z is an antibody. In another embodiment, Z is an antibody comprising glutamine residues. Antibodies comprising glutamine residues can be isolated from natural sources or engineered to comprise one or more glutamine residues. Techniques for engineering glutamine residues into antibody polypeptide chains (glutaminyl-modified antibodies) are within the skill of those in the art. In other embodiments, Z is an N297Q mutant antibody. In further embodiments, Z is an antibody having one or more engineered LLQG, LLQGG, LLQLLQG, LLQYQG, LLQGA, LLQGSG, SLLQG, LQG, LLQLQ, LLQLLQ, LLQGR, LLQYQGA, LQGG, LGQG, or LLQLLQGA sites. See, e.g., U.S. Patent No. 9,676,871 and U.S. Patent Application Publication No. 2003 / 0138785. In certain embodiments, the antibody is aglycosylated. In certain embodiments, Z is an antibody that is a monoclonal antibody, a human antibody, a humanized antibody, a camelized antibody, or a chimeric antibody. In other embodiments, Z is an antibody of any isotype (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass. In some embodiments, Z has a molecular weight of at least 500, 600, 700, 800, 900, 1000, 10,000, 50,000, or 100,000 daltons.
[0067] In other embodiments, antigen-binding domains that can be used in the ADCs provided herein include antibodies, antigen-binding fragments of antibodies, peptides that specifically interact with a particular antigen (e.g., peptibodies), receptor molecules that specifically interact with a particular antigen, proteins comprising the ligand-binding portion of a receptor that specifically binds to a particular antigen, antigen-binding scaffolds (such as, for example, DARPins, HEAT repeat proteins, ARM repeat proteins, tetratricopeptide repeat proteins, and other scaffolds based on naturally occurring repeat proteins (see, e.g., Boersma and Pluckthun, 2011, Curr. Opin. Biotechnol. 22:849-857, and references cited therein)), and aptamers or portions thereof.
[0068] Methods for determining whether two molecules specifically bind to one another are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and similar methods. For example, as used herein, an antigen-binding domain has a K of less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 100 pM, less than about 90 pM, less than about 80 pM, less than about 70 pM, less than about 60 pM, less than about 50 pM, less than about 40 pM, less than about 30 pM, less than about 20 pM, less than about 10 pM, less than about 5 pM, less than about 4 pM, less than about 2 pM, less than about 1 pM, less than about 0.5 pM, less than about 0.2 pM, less than about 0.1 pM, or less than about 0.05 pM, as measured by a surface plasmon resonance assay. D The present invention also includes polypeptides that bind a specific antigen (e.g., a target molecule (T) or an internalization effector protein (E)) or a portion thereof, having the following structure:
[0069] In certain embodiments, the framework regions (FRs) of antibodies or antigen-binding fragments thereof for use in the ADCs provided herein may be identical to human germline sequences or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.
[0070] Methods and techniques for identifying CDRs within HCVR and LCVR amino acid sequences are well known in the art and can be used to identify CDRs. Exemplary rules that can be used to identify CDR boundaries include, for example, the Kabat definition, the Chothia definition, and the AbM definition. In general terms, the Kabat definition is based on sequence variability, the Chothia definition is based on the location of structural loop regions, and the AbM definition is a compromise between the Kabat and Chothia approaches. See, for example, Kabat, "Sequences of Proteins of Immunological Interest," National Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al., J. Mol. Biol. 273:927-948 (1997); and Martin et al., Proc. Natl. Acad. Sci. USA 86:9268-9272 (1989). Public databases are also available for identifying CDR sequences within antibodies.
[0071] Antigen-binding domains for use in the ADCs provided herein may comprise or consist of antigen-binding fragments of intact antibody molecules. Antigen-binding fragments of antibodies may be derived, for example, from intact antibody molecules using any suitable standard technique, such as proteolytic digestion, or recombinant genetic engineering techniques, including the manipulation and expression of DNA encoding the variable and optionally constant domains of an antibody. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage antibody libraries), or can be synthesized. The DNA may be sequenced or engineered using chemical or molecular biology techniques, for example, to arrange one or more variable and / or constant domains in a suitable configuration, or to introduce codons, create cysteine residues, modify, add, or delete amino acids.
[0072] Non-limiting examples of antigen-binding fragments for use in the ADCs provided herein include: (i) Fab fragments, (ii) F(ab')2 fragments, (iii) Fd fragments, (iv) Fv fragments, (v) single-chain Fv (scFv) molecules, (vi) dAb fragments, and (vii) minimal recognition units consisting of amino acid residues that mimic a hypervariable region of an antibody (e.g., an isolated complementarity-determining region (CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide. In other embodiments, antigen-binding fragments of antibodies include domain-specific antibodies, single-domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and other engineered molecules such as shark variable IgNAR domains.
[0073] In certain embodiments, an antigen-binding fragment of an antibody comprises at least one variable domain. A variable domain may be of any size or amino acid composition and will generally comprise at least one CDR adjacent to, or in frame with, one or more framework sequences. H Domain is V L In the antigen-binding fragment associated with the domain, V H Domain and V L The domains can be arranged relative to each other in any suitable configuration. For example, the variable region is a dimer, V H -V H , V H -V L , or V L -V L Alternatively, the antigen-binding fragment of an antibody may contain a dimer of monomeric V H Domain or V L It may also include a domain.
[0074] In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found in an antigen-binding fragment of an antibody for use in the ADCs provided herein include: (i) a V H -C H 1, (ii) V H -C H 2, (iii) V H -C H 3, (iv) V H -C H 1-C H 2. (v) V H -C H 1-C H 2-C H 3. (vi) V H -C H 2-C H 3, (vii)V H -C L , (viii) V L -C H 1, (ix)V L -C H 2. (x)V L -C H 3. (xi) V L -C H 1-C H 2, (xii)V L -C H 1-C H 2-C H 3, (xiii)V L -C H 2-C H 3, and (xiv) V L -C LIn any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be directly linked to each other or may be linked by a full or partial hinge or linker region. The hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that provide a flexible or semi-flexible linkage between adjacent variable and / or constant domains in a single polypeptide molecule. In further embodiments, the antigen-binding fragments may be linked to each other and / or to one or more monomeric V H Domain or V L It may comprise homodimers or heterodimers (or other multimers) of any of the variable and constant domain arrangements listed above, via non-covalent association of the domains (e.g., via disulfide bond(s)).
[0075] In another embodiment, the antigen-binding domain used in the ADCs provided herein may comprise or consist of a human antibody and / or recombinant human antibody, or an antigen-binding fragment thereof.
[0076] In another embodiment, the antigen-binding domain used in the ADCs provided herein may comprise or consist of a recombinant human antibody or antigen-binding fragment thereof. In one embodiment, such a recombinant human antibody has variable and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such a recombinant human antibody is subjected to in vitro mutagenesis (or, if a transgenic animal for human Ig sequences is used, in vivo somatic mutagenesis) to thereby modify the V and C regions of the recombinant antibody. H Area and V L The amino acid sequence of the region is human germline V H Sequence and V L While derived from and related to the sequence, it is a sequence that may not naturally exist within the human antibody germline repertoire in vivo.
[0077] In another embodiment, the antigen-binding domain used in the ADCs provided herein also includes bispecific antigen-binding molecules such as bispecific antibodies. Methods for making bispecific antibodies are known in the art and can be used to construct the bispecific antigen-binding molecules used herein. Exemplary bispecific formats that can be used in the context of the present disclosure include, for example, scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, quadroma, knobs-into-holes, common light chains (e.g., common light chains with knobs-into-holes), CrossMab, CrossFab, (SEED) body, leucine zipper, Duobody, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab. 2Bispecific formats include, but are not limited to, bispecific formats (see, e.g., Klein et al. 2012, mAbs 4:6, 1-11, and the references cited therein for a review of the aforementioned formats). See also, for example, US2018 / 0134794, which discloses bispecific antigen-binding molecules. Briefly, a bispecific antigen-binding molecule may comprise a first antigen-binding domain (also referred to herein as "D1") and a second antigen-binding domain (also referred to herein as "D2"). Simultaneous binding of two distinct epitopes by a bispecific antigen-binding molecule results in effective ligand blockade with minimal activation of target signaling. In certain embodiments, the D1 and D2 domains of a bispecific antibody are non-competitive with each other. Non-competition between D1 and D2 means that the respective monospecific antigen-binding proteins from which D1 and D2 are derived do not compete with each other for binding to the target. Exemplary antigen-binding protein competition assays are known in the art. In certain embodiments, D1 and D2 bind to different (e.g., non-overlapping or partially overlapping) epitopes on the target. Bispecific antigen-binding molecules can be constructed using the antigen-binding domains of two separate monospecific antibodies. For example, a collection of monoclonal monospecific antibodies can be generated using standard methods known in the art. The individual antibodies thus produced can be tested pairwise against each other for cross-competition for the target protein. If two different antibodies can simultaneously bind to the target (i.e., do not compete with each other), the antigen-binding domain from one antibody and the antigen-binding domain from a second, non-competing antibody can be engineered into a single bispecific antibody. A bispecific antigen-binding molecule can be a single multifunctional polypeptide or a multimeric complex of two or more polypeptides that are covalently or non-covalently linked to each other. Any antigen-binding construct capable of simultaneously binding to two distinct, non-identical epitopes on a target molecule is considered a bispecific antigen-binding molecule.Bispecific antigen-binding molecules or variants thereof can be constructed using standard molecular biology techniques (e.g., recombinant DNA and protein expression techniques) that will be known to those skilled in the art. In another embodiment, bispecific antibodies are also provided, in which one arm of the bispecific antibody binds to an epitope on a first target protein and the other arm of the bispecific antibody binds to a second epitope on a second target protein. Other exemplary bispecific formats that can be used in the context of the present disclosure include, but are not limited to, scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, quadroma, knobs-into-holes, common light chains (e.g., common light chains with knobs-into-holes), CrossMab, CrossFab, (SEED) bodies, leucine zipper, Duobody, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab2 bispecific formats (see, e.g., Klein et al. 2012, mAbs 4:6, 1-11, and the references cited therein for a review of the aforementioned formats). Bispecific antibodies can also be constructed using peptide / nucleic acid conjugation, for example, using unnatural amino acids with orthogonal chemical reactivity to generate site-specific antibody-oligonucleotide conjugates that then self-assemble into multimeric complexes with defined composition, valency, and geometry. (See, e.g., Kazane et al., J. Am. Chem. Soc. (Epub: Dec. 4, 2012)).
[0078] In another embodiment, the antigen-binding domain for use in the ADCs provided herein also includes antibodies comprising variants of any of the HCVR, LCVR, and / or CDR amino acid sequences known in the art. In one embodiment, the variants include variants of any of the HCVR, LCVR, and / or CDR amino acid sequences known in the art with one or more conservative substitutions. For example, the antigen-binding domain comprises an antibody or antigen-binding fragment thereof having an HCVR, LCVR, and / or CDR amino acid sequence with, for example, 10 or fewer, 8 or fewer, 6 or fewer, or 4 or fewer conservative amino acid substitutions relative to any of the HCVR, LCVR, and / or CDR amino acid sequences known in the art. In another embodiment, the antigen-binding domain comprises an antibody or antigen-binding fragment thereof, which also includes variants with substantial sequence identity to any of the HCVR, LCVR, and / or CDR amino acid sequences known in the art. In certain embodiments, residue positions that are not identical differ by conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is replaced with another amino acid residue having a side chain with similar chemical properties (e.g., charge or hydrophobicity). Generally, conservative amino acid substitutions do not substantially change the functional properties of protein.When two or more amino acid sequences differ from each other by conservative substitutions, the percentage of sequence identity or degree of similarity can be adjusted upward to correct for the conservative nature of substitution.The means for making this adjustment are well known to those skilled in the art.For example, see Pearson (1994) Methods Mol.Biol.24:307-331, which is incorporated herein by reference. Examples of groups of amino acids having side chains with similar chemical properties include: (1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; (2) aliphatic-hydroxyl side chains: serine and threonine; (3) amide-containing side chains: asparagine and glutamine; (4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; (5) basic side chains: lysine, arginine, and histidine; (6) acidic side chains: aspartic acid and glutamic acid; and (7) sulfur-containing side chains: cysteine and methionine.In one embodiment, conservative amino acid substitutions are valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. In another embodiment, a conservative substitution is any change with a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science 256:1443-1445. A "moderately conservative" substitution is any change with a non-negative value in the PAM250 log-likelihood matrix.
[0079] Sequence identity between two different amino acid sequences is typically measured using sequence analysis software. Sequence analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions, and other modifications, including conservative amino acid substitutions. For example, GCG software contains programs such as GAP and BESTFIT, which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms, or between a wild-type protein and its mutant protein. See, for example, GCG version 6.1. Polypeptide sequences can also be compared using FASTA, a program in GCG version 6.1 with default or recommended parameters. FASTA (e.g., FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of best overlap between the query and search sequences (Pearson (2000) supra). Another algorithm for comparing the sequences provided herein to databases containing multiple sequences from different organisms is the computer program BLAST, specifically BLASTP or TBLASTN, using default parameters. See, e.g., Altschul et al. (1990) J. Mol. Biol. 215:403-410 and Altschul et al. (1997) Nucleic Acids Res. 25:3389-402.
[0080] i. Epitope Mapping and Related Techniques The epitope to which the antigen-binding domain binds may consist of a single contiguous sequence of three or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) amino acids of the target protein. Alternatively, the relevant epitope may consist of multiple non-contiguous amino acids (or amino acid sequences) of the target protein. In some embodiments, the epitope is located at or near the binding domain of the target protein. In other embodiments, the epitope is located outside the binding domain of the target protein.
[0081] Various techniques known to those skilled in the art can be used to determine the epitope with which the antigen-binding domain used in the ADCs provided herein interacts. Exemplary techniques that can be used to determine the epitope or binding domain of a particular antigen-binding domain include, for example, point mutagenesis (e.g., alanine scanning mutagenesis, arginine scanning mutagenesis, etc.), peptide blot analysis (Reineke, 2004, Methods Mol Biol 248:443-463), protease protection, and peptide cleavage analysis. Additionally, methods such as epitope excision, epitope extraction, and chemical modification of antigens can be employed (Tomer, 2000, Protein Science 9:487-496). Another method that can be used to identify the amino acids in a polypeptide with which an antigen-binding domain interacts is hydrogen / deuterium exchange detected by mass spectrometry. Generally speaking, hydrogen / deuterium exchange involves deuterium-labeling a protein of interest and then binding the antigen-binding domain to the deuterium-labeled protein. The protein / antigen-binding domain complex is then transferred to water to allow hydrogen-deuterium exchange to occur at all residues except those protected by the antigen-binding domain (which remain deuterium-labeled). After dissociation of the antigen-binding domain, the target protein is subjected to protease cleavage and mass spectrometry, thereby revealing the deuterium-labeled residues corresponding to the specific amino acids with which the antigen-binding domain interacts. See, for example, Ehring (1999) Analytical Biochemistry 267(2):252-259; Engen and Smith (2001) Anal. Chem. 73:256A-265A. X-ray crystallography can also be used to identify the amino acids in a polypeptide with which the antigen-binding domain interacts.
[0082] ii. Preparation of human antibodies In one embodiment, the antibody used in the ADC provided herein is a fully human antibody.The method for generating monoclonal antibodies, including fully human monoclonal antibodies, is known in the art.Any such known method can be used in the context of the present disclosure to generate the human antibody that specifically binds to human protein target.
[0083] For example, using VELOCIMMUNE™ technology or any other similar known method for generating fully human monoclonal antibodies, high-affinity chimeric antibodies against human protein targets having human variable regions and mouse constant regions are first isolated. The antibodies are characterized and selected for desired characteristics, including affinity, ligand-blocking activity, selectivity, epitope, etc. If necessary, the mouse constant region is replaced with a desired human constant region, such as wild-type or modified IgG1 or IgG4, to generate a fully human antibody. While the constant region selected can vary depending on the particular application, the characteristics of high-affinity antigen binding and target specificity reside in the variable region. In some instances, fully human antibodies are isolated directly from antigen-positive B cells.
[0084] iii. Biological equivalents Antigen-binding domains for use in the ADCs provided herein include proteins with amino acid sequences that differ from those of the described antibodies but retain the ability to bind to a target protein. Such variant antigen-binding domains contain one or more amino acid additions, deletions, or substitutions compared to the parent sequence, but exhibit biological activity that is essentially equivalent to that of the described antibodies.
[0085] Two antigen-binding domains are considered bioequivalents or pharmaceutical substitutes if, for example, they exhibit no significant differences in absorption rate and extent when administered at the same molar dose, either in single or multiple doses, under similar experimental conditions. Some antigen-binding domains may be considered equivalent or pharmaceutical substitutes if their extent of absorption is equivalent but their absorption rate is not, and they can still be considered bioequivalent because such differences in absorption rate are intentional, reflected in the label, are not essential for achieving effective body drug concentrations for long-term use, and are not considered medically significant for the particular drug product tested.
[0086] In one embodiment, two antigen-binding domains are bioequivalent if there are no clinically significant differences in their safety, purity, or potency.
[0087] In one embodiment, two antigen-binding domains are bioequivalent if a patient can make such a switch between the reference product and the biological product one or more times without an expected increase in the risk of adverse effects, including a clinically significant change in immunogenicity or a decrease in efficacy, compared to continuing treatment without switching.
[0088] In one embodiment, two antigen-binding domains are biologically equivalent if they both act by a common mechanism or mode of action for a condition or condition of use, to the extent that such mechanism is known.
[0089] Bioequivalence can be demonstrated by in vivo and in vitro methods. Bioequivalence measurements include, for example, (a) in vivo studies in humans or other mammals in which the concentration of the antigen-binding domain or its metabolites is measured as a function of time in blood, plasma, serum, or other biological fluids, (b) in vitro studies that correlate with and reasonably predict human in vivo bioavailability data, (c) in vivo studies in humans or other mammals in which the relevant acute pharmacological effect of the antigen-binding domain (or its target) is measured as a function of time, and (d) well-controlled clinical studies that establish the safety, efficacy, or bioavailability or bioequivalence of the antigen-binding domain.
[0090] Biologically equivalent variants of antigen-binding domains for use in the ADCs provided herein may be constructed, for example, by substituting various residues or sequences or deleting terminal or internal residues or sequences that are not required for biological activity. For example, cysteine residues that are not essential for biological activity can be deleted or substituted with other amino acids to prevent the formation of unnecessary or incorrect intramolecular disulfide bridges during renaturation. In other contexts, biologically equivalent antigen-binding domains may include variants containing amino acid changes that modify the glycosylation characteristics of the antigen-binding domain, for example, mutations that eliminate or remove glycosylation.
[0091] iv. Species selectivity and species cross-reactivity In certain embodiments, the antigen-binding domain for use in the ADCs provided herein binds to a human target protein but not to target proteins from other species. In other embodiments, the antigen-binding domain for use in the ADCs provided herein binds to a human target protein and a target protein from one or more non-human species. For example, the antigen-binding domain for use in the ADCs provided herein may bind to a human target protein but, in some cases, may or may not bind to one or more of mouse, rat, guinea pig, hamster, gerbil, pig, cat, dog, rabbit, goat, sheep, cow, horse, camel, cynomolgus monkey, marmoset, rhesus monkey, or chimpanzee target proteins. In one embodiment, the antigen-binding domain specifically binds to a human target protein and a cynomolgus monkey (e.g., Macaca fascicularis) target protein. In other embodiments, the antigen-binding domain for use herein binds to a human target protein but does not bind, or only weakly binds, to a cynomolgus monkey target protein.
[0092] v. Exemplary Antibody and Antigen Targets Antibodies for use in the ADCs provided herein can have binding specificity for any antigen (target protein) deemed suitable by one of skill in the art. In certain embodiments, the antigen is a transmembrane molecule (e.g., a receptor). In one embodiment, the antigen is expressed on a tumor. In some embodiments, the binding agent interacts with or binds to a tumor antigen, including an antigen specific to a tumor type or an antigen shared, overexpressed, or modified on a particular type of tumor. In one embodiment, the antigen is expressed on a solid tumor. Exemplary antigens include lipoproteins, alpha 1-antitrypsin, cytotoxic T lymphocyte-associated antigens (CTLA) such as CTLA-4, vascular endothelial growth factor (VEGF), hormone or growth factor receptors, protein A or D, fibroblast growth factor receptor 2 (FGFR2), EpCAM, GD3, FLT3, PSMA, PSCA, MUC1, MUC16, STEAP, STEAP2, CEA, TENB2, EphA receptors, EphB receptors, folate receptors, FOLRI, mesothelin, cripto, alpha beta 6, integrins, VEGF, VEGFR, EGFR, transferrin receptor, IRTA1, IRTA2, IRTA3, IRTA4, IRTA5, CD2, CD3, CD4, CD5, CD6, CD8, CD11, CD14, CD19, CD20, CD21, CD22, CD25, CD26, CD28, CD CD proteins such as CD30, CD33, CD36, CD37, CD38, CD40, CD44, CD52, CD55, CD56, CD59, CD70, CD79, CD80, CD81, CD103, CD105, CD134, CD137, CD138, CD152, or one or more tumor-associated antigens or antigens disclosed in U.S. Publication No. 2008 / 0171040 or U.S. Publication No. 2008 / 0305044. These include antibodies that bind to cell surface receptors, erythropoietin, transforming factors, immunotoxins, bone morphogenetic proteins (BMPs), T-cell receptors, surface membrane proteins, integrins such as CD11a, CD11b, CD11c, CD18, ICAM, VLA-4, and VCAM, AFP, ALK, B7H4, BAGE proteins, β-catenin, brc-abl, BRCA1, BORIS, CA9 (carbonic anhydrase IX),Caspase-8, BCMA, SLAMF7, GPNMB, UPK3A, CD20, CD40, CD123, CDK4, CEA, CLEC12A, c-kit, cMET, CTLA4, cyclin-B1, CYP1B1, EGFR, EGFRvIII, endoglin, Epcam, EphA2, ErbB2 / Her2, ErbB3 / Her3, ErbB4 / Her4, ETV6-AML, Fra-1, FOLR1, GAGE protein, GD2, GD3, GloboH, glypican- 3, GM3, gp100, Her2, HLA / B-raf, HLA / EBNA1, HLA / k-ras, HLA / MAGE-A3, hTERT, IGF1R, LGR5, LMP2, MAGE protein, MART-1, mesothelin, ML-I AP, Muc1, Muc16, CA-125, MUM1, NA17, NGEP, NY-BR1, NY-BR62, NY-BR85, NY-ESO1, OX40, p15, p53, PAP, PAX3, PAX5, PCTA-1, PDGFR-α , PDGFR-β, PDGF-A, PDGF-B, PDGF-C, PDGF-D, PLAC1, PRLR, PRAME, PSCA, PSGR, PSMA (FOLH1), RAGE protein, Ras, RGS5, Rho, SART-1, SART-3, Steap-1, Steap-2, STn, survivin, TAG-72, TGF-β, TMPRSS2, Tn, TNFRSF17, TRP-1, TRP-2, tyrosinase, and uroplakin-3, and any of the above polypeptides. Examples of antigens include, but are not limited to, molecules such as tumor-associated antigens, such as fragments thereof, cell surface-expressed antigens, class A scavenger receptors, including MUC16, c-MET, scavenger receptor A (SR-A), and other membrane proteins, such as B7 family-related members, including V-set and Ig domain-containing 4 (VSIG4), colony-stimulating factor 1 receptor (CSF1R), asialoglycoprotein receptor (ASGPR), and amyloid beta precursor-like protein 2 (APLP-2). In some embodiments, the antigen is PRLR or HER2. In some embodiments, the antigen is HER2. In some embodiments, the antigen is human HER2. In some embodiments, the antigen is STEAP2. In some embodiments, the antigen isIn some examples, the MAGE protein is selected from MAGE-1, -2, -3, -4, -6, and -12. In some examples, the GAGE protein is selected from GAGE-1 and GAGE-2.
[0093] In certain embodiments, the antibody contains a glutamine residue at one or more heavy chain positions numbered 295 in the EU numbering system. In the present disclosure, this position is referred to as glutamine 295, or Gln295, or Q295. Those skilled in the art will recognize that this is a conserved glutamine residue in the wild-type sequences of many antibodies. In other embodiments, the antibody can be engineered to contain a glutamine residue. In certain embodiments, the antibody contains one or more N297Q mutations. Techniques for modifying antibody sequences to contain glutamine residues are within the skill of those skilled in the art (see, e.g., Ausubel et al. Current Protoc. Mol. Biol. (John Wiley & Sons)).
[0094] B. Payload R In one embodiment, R is a therapeutic agent or an imaging agent. In another embodiment, R is a therapeutic agent such as a cytotoxic agent, a chemotherapeutic agent, or a radioisotope. In another embodiment, R is a positron emitter and / or a chelating moiety. In other embodiments, payloads for use in the ADCs provided herein include cytotoxins, anti-inflammatory agents, steroids, glucocorticoids, LXR modulators, antivirals, and antibiotics. In another embodiment, payloads for use in the ADCs provided herein are small molecule compounds, e.g., compounds having a molecular weight of less than 2000 daltons, less than 1500 daltons, less than 1000 daltons, less than 750 daltons, or less than 500 daltons.
[0095] Cytotoxic agents for use as payloads herein include any agent that is detrimental to the growth, viability, or proliferation of cells, including, but not limited to, tubulin-interacting agents and DNA-damaging agents.Examples of suitable cytotoxic and chemotherapeutic agents that can be used in the ADCs provided herein include, for example, 1-(2-chloroethyl)-1,2-dimethanesulfonyl hydrazide, 1,8-dihydroxy-bicyclo(7.3.1)trideca-4,9-diene-2,6-diyn-13-one, 1-dehydrotestosterone, 5-fluorouracil, 6-mercaptopurine, 6-thioguanine, 9-aminocamptothecin, actinomycin D, amanitin, aminopterin, anguidin, anthracyclines, and the like. , anthramycin (AMC), auristatin, bleomycin, busulfan, butyric acid, calicheamicin (e.g., calicheamicin γ1), camptothecin, carminomycin, carmustine, cemadotin, cisplatin, colchicine, combretastatin, cyclophosphamide, cytarabine, cytochalasin B, dactinomycin, daunorubicin, decarbazine, diacetoxypentyldoxorubicin, dibromomannitol, dihydroxyanthracin dione, disorazole, dolastatin ( For example, dolastatins 10), doxorubicin, duocarmycin, echinomycin, eleutherobin, emetine, epothilone, esperamicin, estramustine, ethidium bromide, etoposide, fluorouracil, geldanamycin, gramicidin D, glucocorticoids, irinotecan, kinesin spindle protein (KSP) inhibitors, leptomycin, lulosin, lidocaine, lomustine (CCNU), maytansinoids, mechlorethamine, melphalan, mercaptopurine, methopterin, and methotrexate. Examples include Rexate, mithramycin, mitomycin, mitoxantrone, N8-acetylspermidine, podophyllotoxin, procaine, propranolol, pteridine, puromycin, pyrrolobenzodiazepine (PBD), rhizoxin, streptozotocin, tallysomycin, taxol, tenoposide, tetracaine, thioepachlorambucil, tomaymycin, topotecan, tubulysin, vinblastine, vincristine, vindesine, vinorelbine, and derivatives of any of the foregoing.In certain embodiments, the cytotoxic agent used as a payload in the ADCs provided herein is a maytansinoid such as DM1 or DM4, a tomaymycin derivative, or a dolastatin derivative. In other embodiments, the cytotoxic agent used as a payload in the ADCs provided herein is an auristatin such as MMAE, MMAF, or a derivative thereof. In one embodiment, the cytotoxic agent used as a payload in the ADCs provided herein is MMAE (monomethylolistatin E), which has the following formula: [ka]
[0096] Other cytotoxic agents known in the art are also contemplated for use as payloads in the ADCs provided herein, including, for example, protein toxins such as lysin, C. difficile toxin, Pseudomonas exotoxin, diphtheria toxin, botulinum toxin, bryodin, saporin, pokeweed toxin (i.e., phytolaccatoxin and phytolacchigenin), and others described in Sapra et al., Pharmacol. & Therapeutics, 2013, 138:452-469. In some embodiments, the payload is a maytansinoid, as described in US2019 / 0151323, US2016 / 0375147, US9,950,076, or US10,570,151, or a tubulysin, as described in WO2020 / 132658.
[0097] In certain embodiments, the cytotoxic agent for use in the ADCs provided herein is a maytansinoid, e.g., a derivative of maytansine. Suitable maytansinoids include DM1, DM4, or derivatives, stereoisomers, or isotopic substitutions thereof. Suitable maytansinoids also include those disclosed in WO2014 / 145090A1, WO2015 / 031396A1, US2016 / 0375147A1, and US2017 / 0209591A1.
[0098] In some embodiments, the maytansinoid has the structure: [ka] wherein A is an optionally substituted arylene or heteroarylene.
[0099] In some embodiments, the maytansinoid has the structure: [ka] wherein A is an optionally substituted arylene or heteroarylene.
[0100] In some embodiments, the maytansinoid has the structure: [ka] In the formula, n is an integer from 1 to 12, and R 1 is alkyl.
[0101] In some embodiments, the maytansinoid is [ka] [ka] [ka] is.
[0102] In some embodiments, the maytansinoid has the formula: [ka]
[0103] In some embodiments, the maytansinoid has the formula: [ka]
[0104] In other embodiments, R is a radionuclide. In these embodiments, the ADCs provided herein are antibody-radionuclide conjugates (ARCs). Radionuclides that can be used as payloads herein include, for example: 225 Ac, 212 Bi, 213 Bi, 131 I, 186 Re, 227 Th, 222 Rn, 223 Ra, 224 Ra, and 90 Examples include Y.
[0105] In certain embodiments, the ADCs provided herein have an antigen-binding domain conjugated to a linker-drug composition described in International Patent Application Publication No. WO 2014 / 145090, e.g., compound "7" shown below. [ka]
[0106] Also provided herein is an ADC comprising an antigen-binding domain conjugated to a cytotoxic agent. In certain embodiments, the cytotoxic agent is a maytansinoid. In certain embodiments, the maytansinoid is a compound having the formula: [ka] In the formula, n is an integer from 1 to 12, and R 1 is alkyl. In certain embodiments, the maytansinoid has the formula: [ka]
[0107] In certain embodiments, the cytotoxic agent is a maytansinoid, and the maytansinoid is covalently attached to the antigen-binding domain via a non-cleavable linker. In certain embodiments, the cytotoxic agent is a maytansinoid, and the maytansinoid is covalently attached to the antigen-binding domain via a cleavable linker.
[0108] In another embodiment, the cytotoxic agent is tubulysin. See, e.g., International Patent Publication No. 2020 / 132658. In another embodiment, the cytotoxic agent has the formula: [ka] During the ceremony, R 1 is C1-C 10 is alkyl, R 3 is -C(O)C1-C5 alkyl, -C(O)N(H)C1-C 10 Alkyl, or -(C1-C 10 (Alkylene)-NR 3a R 3b and In the formula, R 3a and R 3b is each independently at each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl can be optionally substituted; R 4 and R 5 are each independently in each occurrence hydrogen or C1-C5 alkyl; R 6 is -OH or -NHNH2, R 7 are each independently in each occurrence hydrogen, —OH, halogen, or —NR 7a R 7b and In the formula, R 7a and R 7b are each independently, in each occurrence, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, acyl, and an amino acid residue, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl can be optionally substituted; R 8 are each independently in each occurrence hydrogen, deuterium, -NHR 9 , or halogen, In the formula, R 9 is hydrogen, —C1-C5 alkyl, or —C(O)C1-C5 alkyl; m is 1 or 2; Q is -CH2- or -O-; When Q is -O-, R 2 is C 1- C 10 Alkyl, C 1- C 10 Alkynyl, -C1-C 10 Alkylene-(5-membered heteroaryl), -C1-C3 alkylene-Q 1- (CH2) n aryl, or C1-C3 hydroxyalkyl, or Q is -CH 2- If R 2 is C5-C 10 Alkyl, C 1- C 10 Alkynyl, -C1-C 10 Alkylene-(5-membered heteroaryl), -C1-C3 alkylene-Q 1- (CH2) n aryl, or C1-C3 hydroxyalkyl, Q 1 is -CH2- or -O-, the heteroaryl is unsubstituted or substituted with alkyl, aminoalkyl, hydroxylalkyl, carboxyalkyl, benzyl, or phenyl; the aryl is unsubstituted or substituted with nitro or amino; n is an integer of 1 to 5.
[0109] In some embodiments, R is a steroid described in US 10,711,032 or WO2019 / 136487, a rifamycin analog described in WO2020 / 132483, or an LXR modulator described in WO2018 / 213082 or WO2020 / 106780.
[0110] In other embodiments, R is a positron emitter and / or a chelating moiety. In one embodiment, the positron emitter includes those that form a stable complex with the chelating moiety and have a suitable physical half-life for immuno-PET imaging purposes. In certain embodiments, the positron emitter is 89 Zr, 68 Ga, 64 Cu, 44 Sc, and 86 Contains Y.
[0111] In certain embodiments, R comprises a chelating moiety. A chelating moiety, as used herein, is a chemical moiety that comprises a moiety capable of chelating a positron emitter, i.e., a moiety capable of reacting with a positron emitter to form a coordinate chelate complex. In certain embodiments, chelating moieties include those that allow efficient loading of specific metals and form metal-chelator complexes that are sufficiently stable in vivo for diagnostic applications, such as immunoPET imaging. In other embodiments, chelating moieties include those that minimize dissociation of the positron emitter and accumulation in mineral bone, plasma proteins, and / or bone marrow deposits to an extent suitable for diagnostic applications.
[0112] Non-limiting examples of chelating moieties for use herein include positron emitters, 89 Zr, 68 Ga, 64 Cu, 44 Sc, and / or86 In other embodiments, the chelating moiety includes those that form a stable complex with Y. In other embodiments, the chelating moiety is a chelating moiety as described in Nature Protocols, 5(4):739, 2010, Bioconjugate Chem., 26(12):2579 (2015), Chem Commun (Camb), 51(12):2301 (2015), Mol. Pharmaceutics, 12:2142 (2015), Mol. Imaging Biol., 18:344 (2015), Eur. J. Nucl. Med. Mol. Imaging, 37:250 (2010), Eur. J. Nucl. Med. Mol. Imaging (2016). doi:10.1007 / s00259-016-3499-x, Bioconjugate Chem., 26(12):2579(2015), WO2015 / 140212A1, and US Pat. No. 5,639,879.
[0113] In other embodiments, the chelating moiety also includes desferrioxamine (DFO), 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA), diethylenediaminetetraacetic acid (DTPA), ethylenediaminetetraacetic acid (EDTA), (1,4,7,10-tetraazacyclodecane-1,4,7,10-tetra(methylenephosphonic) acid (DOTP), (1R,4R,7R,10R)-α'α''α'''α''''-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid ( DOTMA), 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA), H4octapa, H6phospa, H2dedpa, H5decapa, H2azapa, HOPO, DO2A, 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA), 1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane (DOTAM), 1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-dicetic acid (dicetic acid) (CB-TE2A), 1,4,7,10-tetraazacyclododecane (Cyclen), 1,4,8,11-tetraazacyclotetradecane (Cyclam), octadecane chelators, hexadecane chelators, phosphonate-based chelators, macrocyclic chelators, chelators containing macrocyclic terephthalamide ligands, bifunctional chelators, fusarinine C and fusarinine C derivative chelators, triacetylfusarinine C (TAFC), feroxamine E (FOXE), feroxamine B (FOXB), ferrichrome A (FCHA), and others.
[0114] C. Linkers L and L 1 iL In certain embodiments, L is any group or moiety that links, connects, or bonds selenium to the side chain NH of Gln. In one embodiment, L can be conjugated to one or more glutamine residues via transglutaminase-based chemoenzymatic conjugation (e.g., Dennler et al., Bioconjugate Chem. 2014, 25, 569-578). For example, in the presence of transglutaminase, one or more glutamine residues of an antibody can be bound to a primary amine compound, such as a selenium-containing primary amine compound. In certain embodiments, the primary amine is a diselenide, such as (H2N-L-Se)2. In some embodiments, L is any divalent group, including alkylene, alkenylene, cycloalkenylene, arylene, a divalent polyethylene glycol (PEG) group, and combinations thereof.
[0115] In certain embodiments, L has one of the following formulas:
[0116] (CH2) n ,
[0117] (CH2CH2O) n -(CH2) p ,
[0118] (CH2) n -N(H)C(O)-(CH2) m ,
[0119] (CH2CH2O) n -N(H)C(O)-(CH2CHO) m -(CH2) p ,
[0120] (CH2) n -C(O)N(H)-(CH2) m ,
[0121] (CH2CH2O) n -C(O)N(H)-(CH2CH2O) m -(CH2)p ,
[0122] (CH2) n -N(H)C(O)-(CH2CHO) m -(CH2) p ,
[0123] (CH2CH2O) n -N(H)C(O)-(CH2) m ,
[0124] (CH2) n -C(O)N(H)-(CH2CH2O) m -(CH2) p , and
[0125] (CH2CH2O) n -C(O)N(H)-(CH2) m ,
[0126] In the formula, n is an integer selected from 1 to 12,
[0127] m is an integer selected from 0 to 12;
[0128] p is an integer selected from 0 to 2.
[0129] In another embodiment, L is alkylene. In another embodiment, L is ethylene.
[0130] ii.L 1 In certain embodiments, L 1is any group or moiety that links, connects, or bonds selenium to a payload. Suitable linkers can be found, for example, in Antibody-Drug Conjugates and Immunotoxins, Phillips, GL, Ed.; Springer Verlag: New York, 2013; Antibody-Drug Conjugates, Ducry, L., Ed.; Humana Press, 2013; Antibody-Drug Conjugates, Wang, J., Shen, W.-C, and Zaro, JL, Eds.; Springer International Publishing, 2015. In certain embodiments, the L of the ADCs provided herein 1 The linker group L is stable enough to exploit the circulating half-life of the antigen-binding domain, while at the same time being able to release its payload after antigen-mediated internalization of the ADC. 1 L may be cleavable or non-cleavable. 1 Cleavable linkers for use as include linkers that are cleaved by intracellular metabolism after internalization, such as cleavage via hydrolysis, reduction, or enzymatic reaction. 1 Non-cleavable linkers for use as L include linkers that release the attached payload via lysosomal degradation of the antigen-binding domain after internalization. 1 Linkers include, but are not limited to, acid labile linkers, hydrolytically labile linkers, enzymatically cleavable linkers, reduction labile linkers, self-immolative linkers, and non-cleavable linkers. 1 Linkers include, but are not limited to, linkers that are or include peptides, carbohydrates, glucuronides, polyethylene glycol (PEG) units, hydrazones, mal-caproyl units, dipeptide units, valine-citrulline units, and para-aminobenzyl (PAB) units.
[0131] Any linker molecule or linker technology known in the art can be used in conjunction with the L2 linkers to make or construct the ADCs provided herein. 1 In certain embodiments, L 1 The linker is a cleavable linker. 1 The linker is a non-cleavable linker. In certain embodiments, the L that may be used in the ADCs provided herein 1 Linkers include, for example, linkers comprising or consisting of MC (6-maleimidocaproyl), MP (maleimidopropanoyl), val-cit (valine-citrulline), val-ala (valine-alanine), a dipeptide moiety in a protease-cleavable linker, ala-phe (alanine-phenylalanine), a dipeptide moiety in a protease-cleavable linker, PAB (p-aminobenzyloxycarbonyl), and variants and combinations thereof. 1 Further examples of linkers are disclosed, for example, in U.S. Pat. No. 7,754,681 and Ducry, Bioconjugate Chem., 2010, 21:5-13, and references cited therein.
[0132] In certain embodiments, L 1 The linker is stable under physiological conditions. In certain embodiments, L 1 The linker may be cleavable, e.g., capable of releasing at least the payload portion in the presence of an enzyme or at a particular pH range or value. 1 The linker comprises an enzyme-cleavable moiety. In one embodiment, the enzyme-cleavable L 1 Linkers include, but are not limited to, peptide bonds, ester bonds, and hydrazones. 1 The linker comprises a cathepsin-cleavable linker.
[0133] In some embodiments, L 1The linker comprises a non-cleavable moiety.
[0134] In some embodiments, L 1 The linker comprises one or more amino acids. Suitable amino acids include natural, unnatural, standard, non-standard, proteinogenic, non-proteinogenic, and L- or D-α-amino acids. In some embodiments, L 1 The linker comprises alanine, valine, glycine, leucine, isoleucine, methionine, tryptophan, phenylalanine, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or citrulline, derivatives thereof, or combinations thereof. In certain embodiments, one or more amino acid side chains are linked to the side chains described below. In some embodiments, the linker comprises valine and citrulline. In some embodiments, L 1 The linker comprises lysine, valine, and citrulline. 1 The linker comprises lysine, valine, and alanine. 1 The linker comprises valine and alanine.
[0135] In some embodiments, L 1 The linker comprises a self-immolative group. The self-immolative group can be any such group known to those skilled in the art. In certain embodiments, the self-immolative group is p-aminobenzyl (PAB) or a derivative thereof. Useful derivatives include p-aminobenzyloxycarbonyl (PABC). Those skilled in the art will appreciate that the self-immolative group can be used to remove L from the payload. 1 It will be appreciated that a chemical reaction can be carried out that releases the remaining atoms of the linker.
[0136] In other embodiments, L 1 The group may be modified with one or more enhancement groups. In certain embodiments, the enhancement group is L 1The facilitating group can be linked to the side chain of any amino acid in the nucleotide sequence. In one embodiment, amino acids for linking the facilitating group include lysine, asparagine, aspartic acid, glutamine, glutamic acid, and citrulline. The linkage to the facilitating group can be a direct linkage to the amino acid side chain, or the linkage can be indirect via a spacer and / or a reactive group. In one embodiment, the spacer and reactive group include any of those described herein. In certain embodiments, the facilitating group can be any group that imparts a beneficial effect to the payload, linker payload, or ADC, including, but not limited to, biological, biochemical, synthetic, solubilizing, imaging, detection, and reactivity effects. In certain embodiments, the facilitating group is a hydrophilic group. In certain embodiments, the facilitating group is a cyclodextrin. In certain embodiments, the facilitating group is an alkyl, heteroalkyl, alkenyl, heteroalkenyl, sulfonic acid, heteroalkenyl taurine, heteroalkenyl phosphate or phosphate, heteroalkenyl amine (e.g., a quaternary amine), or heteroalkenyl sugar. In certain embodiments, sugars include, but are not limited to, monosaccharides, disaccharides, and polysaccharides. Exemplary monosaccharides include glucose, ribose, deoxyribose, xylose, arabinose, mannose, galactose, fructose, and the like. In certain embodiments, sugars include sugar acids such as glucuronic acid, further including conjugated forms (i.e., via glucuronidation) such as glucuronides. Exemplary disaccharides include maltose, sucrose, lactose, trehalose, and the like. Exemplary polysaccharides include amylose, amylopectin, glycogen, inulin, cellulose, and the like. The cyclodextrin can be any cyclodextrin known to those of skill in the art. In certain embodiments, the cyclodextrin is alpha cyclodextrin, beta cyclodextrin, or gamma cyclodextrin, or a mixture thereof. In certain embodiments, the cyclodextrin is alpha cyclodextrin. In certain embodiments, the cyclodextrin is a beta cyclodextrin.In certain embodiments, the cyclodextrin is gamma cyclodextrin. In certain embodiments, the enhancing group can improve the residual solubility of the ADC. In certain embodiments, the alkyl, heteroalkyl, alkenyl, or heteroalkenyl sulfonic acid is substituted or unsubstituted. In certain embodiments, the alkyl, heteroalkyl, alkenyl, or heteroalkenyl sulfonic acid is -(CH2)1-5SO3H, -(CH2). n -NH-(CH2)1-5SO3H, -(CH2) n -C(O)NH-(CH2)1-5SO3H, -(CH2CH2O) m -C(O)NH-(CH2) 1-5 SO3H,-(CH2) n -N(CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, -(CH2) n -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, or -(CH2CH2O) m -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, n is 1, 2, 3, 4, or 5, and m is 1, 2, 3, 4, or 5. In one embodiment, the alkyl or alkenyl sulfonic acid is -(CH2) 1-5 In another embodiment, the heteroalkyl or heteroalkenyl sulfonic acid is —(CH) n -NH-(CH2) 1-5 SO3H, and n is 1, 2, 3, 4, or 5. In another embodiment, the alkyl, heteroalkyl, alkenyl, or heteroalkenyl sulfonic acid is -(CH2) n -C(O)NH-(CH2) 1-5 SO3H, and n is 1, 2, 3, 4, or 5. In another embodiment, the alkyl, heteroalkyl, alkenyl, or heteroalkenyl sulfonic acid is -(CH2CH2O)m -C(O)NH-(CH2) 1-5 SO3H and m is 1, 2, 3, 4, or 5. In another embodiment, the alkyl, heteroalkyl, alkenyl, or heteroalkenyl sulfonic acid is -(CH2) n -N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H2, and n is 1, 2, 3, 4, or 5. In another embodiment, the alkyl, heteroalkyl, alkenyl, or heteroalkenyl sulfonic acid is -(CH2) n -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H2, and n is 1, 2, 3, 4, or 5. In another embodiment, the alkyl, heteroalkyl, alkenyl, or heteroalkenyl sulfonic acid is -(CH2CH2O) m -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H2, and m is 1, 2, 3, 4, or 5.
[0137] III. Synthesis of ADCs Also provided herein are methods for synthesizing the ADCs provided herein, the methods comprising reacting a glutamine-containing antigen-binding domain with a diselenide of formula (HN-L-Se) to provide a compound of Formula II: [ka]
[0138] wherein Z is an antigen-binding domain;
[0139] each [ka] is the side chain of Gln, and L is a linker. In one embodiment, the reaction of the antigen-binding domain and the diselenide is mediated by a transglutaminase enzyme. In another embodiment, the transglutaminase enzyme is mouse transglutaminase enzyme. In another embodiment, when the Gln in the antigen-binding domain is Q295 of the N297 antibody, the antigen-binding domain is reacted with PNGase, such as, but not limited to, PNGase F, to deglycosylate N297 prior to the reaction of the antigen-binding domain with the diselenide.
[0140] In one embodiment, the compound of Formula II is then reacted with a reducing agent at a pH of 6 or less to form a reduced diselenide. In another embodiment, the reaction of the compound of Formula II with the reducing agent is carried out at a pH of 5 or less, or 4 or less. In one embodiment, the reducing agent is tris(2-carboxyethyl)phosphine (TCEP). In another embodiment, the reduction of the diselenide is carried out by reacting L 1 -R, L 1 contains a group that reacts with reduced diselenide to form a covalent bond. In one embodiment, the group that reacts with reduced diselenide is a maleimide group, an iodoacetamide group, or a bromoacetamide group. In one embodiment, the group that reacts with reduced diselenide is a maleimide group. In a further embodiment, L 1 Reduction of a compound of Formula II in the presence of —R produces the ADCs provided herein.
[0141] Thus, in one embodiment, in the method of synthesizing an ADC provided herein, optionally, when the Gln of Z-Gln is Q295 of the N297 antibody, prior to step (a), Z-Gln is reacted with PNGaseF to deglycosylate N297, and then
[0142] (a) reacting Z-Gln with (H2N-L-Se)2 and mouse transglutaminase to form a compound of formula II: [ka]
[0143] (b) reacting the product of step (a) with a reducing agent at a pH of 6 or less to produce L 1 -R, forming a reduced diselenide, 1 contains a group that reacts with the reduced diselenide to form a covalent bond, thereby forming Z-Gln-NH-L-Se-L 1 Provided herein are methods for forming -R.
[0144] In another embodiment, in the method of synthesizing an ADC provided herein, optionally, when Gln of Z-Gln is Q295 of the N297 antibody, prior to step (a), Z-Gln is reacted with PNGaseF to deglycosylate N297, and then
[0145] (a) reacting Z-Gln with (H2N-L-Se)2 and mouse transglutaminase to form a compound of formula II: [ka]
[0146] (b) reacting the product of step (a) with TCEP at a pH of 6 or less to give L 1 -R, forming a reduced diselenide, 1 contains a maleimide group that reacts with the reduced diselenide to form a covalent bond, thereby forming Z-Gln-NH-L-Se-L 1 Provided herein are methods for forming -R.
[0147] In another embodiment, provided herein is a method of synthesizing the ADCs provided herein according to the method shown in FIG.
[0148] In another embodiment, provided herein is a compound prepared by the methods disclosed herein. In one embodiment, the compound prepared by the processes disclosed herein is a compound of Formula II: [ka]
[0149] In another embodiment, the compound prepared by the processes disclosed herein has the following formula IIa: [ka]
[0150] IV. Pharmaceutical Compositions The pharmaceutical compositions provided herein contain a therapeutically effective amount of one or more ADCs provided herein and a pharmaceutically acceptable carrier.
[0151] The ADC can be formulated into a suitable pharmaceutical preparation. Typically, the ADC is formulated into a pharmaceutical composition using techniques and procedures well known in the art (see, for example, Ansel Introduction to Pharmaceutical Dosage Forms, Seventh Edition 1999).
[0152] In the compositions, an effective concentration of one or more ADCs or pharmaceutically acceptable salts is mixed with a suitable pharmaceutical carrier. In certain embodiments, the concentration of ADC in the composition is effective to deliver an amount that, upon administration, treats, prevents, or ameliorates one or more of the symptoms and / or progression of a disease or disorder disclosed herein.
[0153] Typically, the composition is formulated for administration in a single dose.To formulate the composition, the weight fraction of the ADC is dissolved, suspended, dispersed or otherwise mixed in the selected carrier at an effective concentration to alleviate or improve the condition to be treated.The pharmaceutical carrier suitable for administering the ADC provided herein includes any such carrier known to those skilled in the art to be suitable for a specific administration mode.
[0154] In some embodiments, the ADC is included in a pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the treated subject. The therapeutically effective concentration can be empirically determined by testing the compound in in vitro and in vivo systems described herein and known to those skilled in the art, and then extrapolated therefrom to human dosages. In some embodiments, the ADC is administered in a manner to achieve a therapeutically effective concentration of the payload. In some embodiments, a companion diagnostic (e.g., Olsen D and Jorgensen JT, Front. Oncol., 2014 May 16, 4:105, doi:10.3389 / fonC.2014.00105) is used to determine the therapeutic concentration and safety profile of the ADC in a particular subject or subject population.
[0155] The concentration of the ADC in the pharmaceutical composition will depend on the absorption, tissue distribution, inactivation, and excretion rates of the ADC, the physicochemical properties of the ADC, the administration schedule, and the amount administered, as well as other factors known to those skilled in the art, e.g., the amount delivered will be sufficient to ameliorate one or more symptoms of the diseases or disorders disclosed herein.
[0156] The composition may be administered at once, or may be divided into several smaller doses that are administered at intervals.It is understood that the exact dosage and duration of treatment are a function of the disease being treated and can be empirically determined using known testing protocols or by extrapolating from in vivo or in vitro test data.It should be noted that concentration and dosage values may also vary depending on the severity of the condition being alleviated.It should further be understood that for any particular subject, specific dosage regimens should be adjusted over time according to individual needs and the professional judgment of the person administering or supervising the administration of the composition.
[0157] The compositions may include other active compounds to obtain desired combinations of properties. The ADCs provided herein, or pharmaceutically acceptable salts thereof described herein, may also be advantageously administered, for therapeutic or prophylactic purposes, in conjunction with another agent known in the general art to be of value in the treatment of one or more of the diseases or conditions mentioned herein. It will be understood that such combination therapy constitutes a further aspect of the compositions and methods of treatment provided herein.
[0158] V. Medication The compounds and pharmaceutical compositions provided herein may be administered in certain therapeutically or prophylactically effective amounts, at certain time intervals, in certain dosage forms, and by certain dosage administration methods, as described below.
[0159] The methods provided herein encompass treating patients regardless of the subject's age, although some diseases or disorders are more prevalent in certain age groups.
[0160] An ADC provided herein, or a pharmaceutically acceptable salt thereof, can be administered repeatedly as necessary, for example, until the subject experiences stable disease or regression, or until the subject experiences disease progression or unacceptable toxicity.
[0161] The ADCs provided herein, or pharmaceutically acceptable salts thereof, can be administered once daily (QD) or divided into multiple daily doses, such as twice daily (BID), three times daily (TID), and four times daily (QID). Additionally, administration can be continuous (i.e., daily for consecutive days, or every day), intermittent, e.g., cyclical (i.e., with a rest period of several days, weeks, or months). As used herein, the term "daily" is intended to mean that a therapeutic compound, e.g., an ADC provided herein, or a pharmaceutically acceptable salt thereof, is administered, e.g., once or more times daily for a period of time. The term "continuously" is intended to mean that a therapeutic compound, such as an ADC provided herein, or a pharmaceutically acceptable salt thereof, is administered daily for an uninterrupted period of at least 10 days to 52 weeks. As used herein, the terms "intermittent" or "intermittently" are intended to mean stopping and starting at either regular or irregular intervals. For example, intermittent administration of an ADC provided herein, or a pharmaceutically acceptable salt thereof, can be administration 1 to 6 days per week, administration in cycles (e.g., daily administration for 2 to 8 weeks followed by a rest period of up to 1 week without administration), or administration on alternating days. As used herein, the term "cycling" is intended to mean that a therapeutic compound, such as an ADC provided herein, or a pharmaceutically acceptable salt thereof, is administered daily or continuously, with a rest period between. In some such embodiments, administration is once daily for 2 to 6 days, followed by a rest period of 5 to 7 days without administration.
[0162] VI. Treatment method In another embodiment, a method of treating a subject with an ADC provided herein, or a pharmaceutically acceptable salt thereof, is provided. In another embodiment, a method of treating a subject with a pharmaceutical composition comprising an ADC provided herein, or a pharmaceutically acceptable salt thereof, is provided. The pharmaceutical composition comprises any of the ADCs disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0163] The ADCs provided herein are useful, inter alia, for the treatment, prevention, and / or amelioration of any disease or disorder associated with or mediated by the expression, signaling, or activity of the target protein of the antigen-binding domain.
[0164] In certain embodiments, when the payload is a cytotoxic agent, the ADCs provided herein may be used to treat primary and / or metastatic tumors arising in the brain and meninges, oropharynx, lungs and bronchial tree, gastrointestinal tract, male and female reproductive tract, muscle, bone, skin and adnexa, connective tissue, spleen, immune system, blood-forming cells and bone marrow, liver and urinary tract, and special sensory organs such as the eye. In certain embodiments, the ADCs provided herein are used to treat one or more of the following cancers: acute myeloid leukemia, adult T-cell leukemia, astrocytoma, bladder cancer, breast cancer, PRLR-positive (PRLR+) breast cancer, cervical cancer, cholangiocarcinoma, chronic myeloid leukemia, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, glioblastoma, head and neck cancer (e.g., head and neck squamous cell carcinoma (HNSCC)), Kaposi's sarcoma, kidney cancer, leiomyosarcoma, liver cancer, lung cancer ( For example, small cell lung cancer, non-small cell lung cancer (NSCLC), lymphoma, malignant tumor, malignant glioma, malignant mesothelioma, melanoma, mesothelioma, malignant mesothelioma, MFH / fibrosarcoma, multiple myeloma, nasopharyngeal carcinoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, castration-resistant prostate cancer, renal cell carcinoma, residual cancer (meaning one or more cancerous cells are present or persist in a subject after anti-cancer treatment), rhabdomyosarcoma, small cell lung cancer, gastric cancer, synovial sarcoma, thyroid cancer, uterine cancer, Wilms' tumor. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is prostate cancer.
[0165] In the context of the methods of treatment provided herein, the ADCs may be administered as monotherapy (i.e., as the only therapeutic agent) or in combination with one or more additional therapeutic agents (examples of which are described elsewhere herein).
[0166] VII. Combination Therapy with a Second Active Agent Provided herein are compositions comprising any of the ADCs provided herein in combination with one or more additional therapeutically active ingredients, and methods of treatment comprising administering such combinations to a subject.
[0167] The ADCs provided herein may be used in combination with other MET antagonists (e.g., anti-MET antibodies (e.g., onartuzumab, emibutuzumab, and H4H14639D) or small molecule inhibitors of MET), EGFR antagonists (e.g., anti-EGFR antibodies (e.g., cetuximab or panitumumab) or small molecule inhibitors of EGFR (e.g., gefitinib or erlotinib)), antagonists of another EGFR family member such as Her2 / ErbB2, ErbB3, or ErbB4 (e.g., anti-ErbB2 (e.g., trastuzumab or T-DM1 {KADCYLA®}), anti-ErbB3, or anti-ErbB4 antibodies, or small molecule inhibitors of ErbB2, ErbB3, or ErbB4 activity). inhibitors), EGFRvIII antagonists (e.g., anti-EGFRvIII antibodies), IGF1R antagonists (e.g., anti-IGF1R antibodies), B-raf inhibitors (e.g., vemurafenib, sorafenib, GDC-0879, PLX-4720), PDGFR-α inhibitors (e.g., anti-PDGFR-α antibodies), PDGFR-β inhibitors (e.g., anti-PDGFR-β antibodies, or small molecule kinase inhibitors such as, for example, imatinib mesylate or sunitinib malate), PDGF ligand inhibitors (e.g., anti-PDGF-A, -B, -C, or -D antibodies, aptamers, siRNA, etc.), VEGF antagonists (e.g., VEGF-Trap such as aflibercept, e.g., U.S. Pat. No. 7,087,087,See, e.g., 411 (also referred to herein as "VEGF-inhibitory fusion proteins"), anti-VEGF antibodies (e.g., bevacizumab), small molecule kinase inhibitors of VEGF receptors (e.g., sunitinib, sorafenib, or pazopanib)), DLL4 antagonists (e.g., anti-DLL4 antibodies disclosed in US2009 / 0142354), Ang2 antagonists (e.g., anti-Ang2 antibodies disclosed in US2011 / 0027286, such as H1H685P), FOLH1 antagonists (e.g., anti-FOLH1 antibodies), STEAP1 or STEAP2 antagonists (e.g., anti-STEAP1 antibodies or anti-STEAP2 antibodies), TMPRSS2 antagonists (e.g., anti-TMPRSS2 antibodies), MSLN antagonists (e.g., anti-MSLN antibodies), CA9 antagonists, or a combination thereof. The therapeutic agent may be co-formulated with and / or administered in combination with one or more additional therapeutically active ingredient(s) selected from the group consisting of an anti-CD20 antagonist (e.g., an anti-CA9 antibody), an anti-CA9 antibody, an anti-uroplakin (e.g., an anti-UPK3A) antibody, an anti-MUC16 antagonist (e.g., an anti-MUC16 antibody), an anti-Tn antigen antagonist (e.g., an anti-Tn antibody), an anti-CLEC12A antagonist (e.g., an anti-CLEC12A antibody), an anti-TNFRSF17 antagonist (e.g., an anti-TNFRSF17 antibody), an LGR5 antagonist (e.g., an anti-LGR5 antibody), a monovalent CD20 antagonist (e.g., a monovalent anti-CD20 antibody such as rituximab), a CD20xCD3 bispecific antibody, a PD-1 inhibitor (e.g., an anti-PD-1 antibody such as pembrolizumab or nivolumab), and the like. Other agents that may be beneficially administered in combination with the antibodies provided herein include, for example, tamoxifen, aromatase inhibitors, and cytokine inhibitors, including small molecule cytokine inhibitors and antibodies that bind to cytokines such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-11, IL-12, IL-13, IL-17, IL-18, or their respective receptors.
[0168] By way of example, a PD-1 inhibitor, such as an anti-PD-1 antibody, may be combined with an ADC described herein.
[0169] In another embodiment, provided herein are pharmaceutical compositions comprising any of the ADCs provided herein in combination with one or more chemotherapeutic agents. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (Cytoxan™), alkylsulfonates such as busulfan, improsulfan, and piposulfan, aziridines such as benzodopa, carboquone, metredopa, and uredopa; ethyleneimines and methylameramines, including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolmelamine; triethylenephosphoramide, clarolambucil, Nitrogen mustards such as chlornaphazine, clofosfamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, nobembine, phenesterine, prednimustine, trofosfamide, and uracil mustard; nitroureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; aclacinomycin, actinomycin, autramycin, azaserine, bleomycin, cactinomycin, calicheamicin, and carabimycin cin, carminomycin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin, mycophenolic acid, nogalamycin, ovomycin, peplomycin, potfilomycin, puromycin, chelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zonomycin, Antibodies such as rubicin, antimetabolites such as methotrexate and 5-fluoroucil (5-FU), folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate, purine analogues such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate,Androgens such as epitiostanol, mepitiostane, and testolactone; antiadrenal drugs such as aminoglutethimide, mitotane, and trilostane; folic acid supplements such as floric acid; aceglatone, aldophosphamide glycoside, aminolevulinic acid, amsacrine, Bestravcil, bisantrene, edatlaxate, defoamin, demecolcine, diazicon, elfornithine, elliptinium acetate, etoglucide, gallium nitrate, hydroxyurea, lentinan, lonidamine, mitoguazone, mitoxantrone, mopidamol, and nitracrine , pentostatin, phenamet, pirarubicin, podophyllic acid, 2-ethylhydrazide, procarbazine, PSK™ razoxane, sizofiran, spirogermanium, tenuazonic acid, triaziconazole, 2,2',2''-trichlorotriethylamine, urethane, vindesine, dacarbazine, manomustine, mitobronitol, mitolactol, pipobroman, gacytosine, arabinoside ("Ara-C"), cyclophosphamide, thiotepa, taxanes, e.g., paclitaxel (Taxol™, Bristol-Myers Squibb), Squibb Oncology, Princeton, NJ) and docetaxel (Taxotere™, Aventis Antony, France), chlorambucil, gemcitabine, 6-thioguanine, mercaptopurine, methotrexate, platinum analogs such as cisplatin and carboplatin, vinblastine, platinum, etoposide (VP-16), ifosfamide, mitomycin C, mitoxantrone, vincristine, vinorelbine, navelbine, novantrone, teniposide, daunomycin, aminopterin, xeloda, ibandronate, CPT-11, the topoisomerase inhibitor RFS2000, difluoromethylornithine (DMFO), retinoic acid, esperamycin, capecitabine, and pharmaceutically acceptable salts, acids, or derivatives of any of the above. This definition also includes antihormonal agents that act to regulate or inhibit the action of hormones on tumors, such as tamoxifen, raloxifene, aromatase-inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifen, keoxifen, LY117018, onapristone,and toremifene (Fareston), and antiandrogens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin, as well as pharmaceutically acceptable salts, acids, or derivatives of any of the foregoing.
[0170] The ADCs provided herein may also be administered in combination with, and / or co-formulated with, antivirals, antibiotics, analgesics, corticosteroids, steroids, oxygen, antioxidants, COX inhibitors, cardioprotectants, metal chelators, IFN-gamma, and / or NSAIDs.
[0171] The additional therapeutically active ingredient(s), for example, any of the above-mentioned agents or derivatives thereof, may be administered immediately before, simultaneously with, or immediately after administration of the ADCs provided herein. In another embodiment, pharmaceutical compositions are provided in which the ADCs provided herein are co-formulated with one or more of the additional therapeutically active ingredient(s) described herein.
[0172] As used herein, the term "in combination" includes the use of two or more therapies (e.g., one or more prophylactic and / or therapeutic agents). However, the use of the term "in combination" does not restrict the order in which therapies (e.g., prophylactic and / or therapeutic agents) are administered to a subject with a disease or disorder. A first therapy (e.g., an ADC provided herein) can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concurrently with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) a second therapy (e.g., a prophylactic or therapeutic agent) to a subject. Triple therapies are also contemplated herein.
[0173] The administration of a compound provided herein, or a derivative thereof, and one or more second active agents to a subject can be performed simultaneously or sequentially by the same or different administration routes. The suitability of a particular administration route for a particular active agent depends on the active agent itself (e.g., whether it can be administered orally without being degraded before entering the bloodstream) and the disease or disorder being treated.
[0174] VIII. Working Examples The following examples are intended to illustrate certain embodiments provided herein, and are not intended to limit the scope of the disclosure.
[0175] Example 1 Antibody deglycosylation
[0176] Two antibodies, an anti-HER2 antibody with variable regions derived from humAb4D5-8 of Carter et al., PNAS 1992, 89, 4285 (mAb1), and a non-binding isotype control derived from an immunological antigen unrelated to oncology (ISOmAb), were deglycosylated overnight with 400 U / mg of PNGaseF (NEB P0704L) in PBS pH 7.4 at 37°C. The reaction mixture was buffer exchanged into PBS pH 7.4 using a spin filter (Amicon, 30 kDa cutoff). This allowed access to the 295Q residue with the transglutaminase enzyme described in Example 2, allowing conjugation of the antibody to a maximum of 2 loads.
[0177] Example 2 Bacterial transglutaminase binding of selenocystamine
[0178] Deglycosylated ISOmAb (degly-ISOmAb) and deglycosylated mAb1 (degly-mAb1) antibodies (Example 1) were conjugated at 1 mg / mL in PBS pH 7.4. Selenocystamine (Compound 1, Catalog No. S0520, Sigma-Aldrich) was added to the antibody in a 3-fold molar excess. The enzymatic reaction was initiated by adding 12 units of bacterial transglutaminase (Zedira, T1001) per mg of antibody and incubated at 37°C for 4 to 16 hours. The resulting conjugates were purified by ion-exchange chromatography (GE Capto S ImpRes using a gradient of 20 mM NaOAc, pH 5 and 0 M NaCl to 0.5 M NaCl) and buffer exchanged into 20 mM NaOAc, pH 5. The conjugates (degly-ISOmAb-1 and delgy-mAb1-1) were analyzed by ESI-MS to determine the linker-antibody ratio (LAR) using a Waters Acquity UPLC. Chromatographic separation was achieved on a C4 column (2.1 x 50 mm ACQUITY UPLC BEH Protein C4, 1.7 μm, 300 Å) with a 10-minute gradient (minutes: percentage of mobile phase B, 0:10%, 1:10%, 5:90%, 7:90%, 7.2:10%, 10:10%). Mobile phase A was 0.1% formic acid in water, and mobile phase B was 0.1% formic acid in acetonitrile. The flow rate was set at 0.3 mL / min. The detector time-of-flight (TOF) scan was set from m / z 500 to 4500 using the following key parameters: capillary voltage 3.0 kV, sampling cone 80 V, source offset at 100 V, source temperature 150 °C, desolvation temperature 450 °C, cone gas 0 L / hr, and desolvation gas 800 L / hr. Spectra were deconvolved with the MaxEnt function in MassLynx software. The resulting molecular ions, when weighted according to intensity, corresponded to the charges listed in Table 1. The actual mass spectra are listed in Figures 2A and 2B and Figure 3. Size-exclusion HPLC confirmed that all conjugates were >95% monomeric (Table 3).
[0179] Table 1. Summary of intensity-weighted average linker loading in ISOmAb and mAb1 complexes for selenocystamine binding. [Table 1]
[0180] Experimental Example 3 mc-VC-PAB-MMAE linker-payload conjugates
[0181] Selenocystamine antibody (Example 2) was conjugated at 3-5 mg / mL in 50 mM NaOAc, pH 5, and 10% DMSO. The linker payload (mc-VC-PAB-MMAE, Doronina, SO et al., Nat. Biotechnol., 2003, 21, 778) was added at a 12-fold molar excess relative to the antibody, and tris(2-carboxyethyl)phosphine (TCEP) was added at a 3-fold molar excess relative to the antibody. The reaction was incubated at room temperature for 1 hour. The conjugate was purified by size-exclusion chromatography (SEC). The drug-to-antibody ratio (DAR) was determined by LC-MS (according to the method described in Example 2). The resulting molecular ions, when weighted according to intensity, corresponded to the charges listed in Table 2. The actual mass spectra are listed in Figures 2A and 2B and Figure 3. Size exclusion HPLC (SEC) demonstrated that all conjugates were >93% monomeric (Table 3, Figure 4).
[0182] Table 2. Summary of intensity-weighted average linker-payload loading in degly-ISOmAb-1-mc-vc-PAB-MMAE and degly-mAb1-1-mc-vc-PAB-MMAE conjugates. [Table 2]
[0183] Table 3. Purity (SEC) and DAR (ESI-MS) of 1-mc-vc-PAB-MMAE complex. [Table 3]
[0184] Example 4 In vitro cytotoxicity assay
[0185] The ability of various antibody-drug conjugates and naked payloads to kill antigen-expressing tumor cells in vitro was evaluated.
[0186] SKBR3 (Her2+) cells were seeded in 96-well plates at 8,000 cells per well in complete growth medium and grown overnight. For cell viability curves, serially diluted complexes or naked payloads were added to the cells at final concentrations ranging from 100 nM to 5 pM and incubated for 3 days. NCI H1975 (Her2-) cells were run as a negative control using similar conditions. To measure viability, cells were incubated with CCK8 (Dojindo) for the last 2 hours and analyzed at 450 nm (OD). 450 The absorbance at 1000 nm was measured on a Victor (Perkin Elmer). The background OD determined from digitonin (40 nM)-treated cells was 450 The IC levels were subtracted from all wells and survival was expressed as a percentage of the untreated control. 50 was determined from a four-parameter logistic equation with a 10-point response curve (GraphPad Prism). IC of degly-mAb1-1-mc-vc-PAB-MMAE 50 The IC value for the interchain disulfide complex was 0.035 nM. The IC value for the transglutaminase site-specific selenocystamine complex was similar to that of the transglutaminase site-specific selenocystamine complex. 50 This indicates that the selenocystamine conjugate did not affect the function of the antibody-drug conjugate. 50 Values were corrected for payload equivalents, and the cell viability results are shown in Table 4 and Figure 5. For comparison, mc-vc-PAB-MMAE interchain disulfide conjugates were prepared according to Doronina, SO et al., Nat. Biotechnol., 2003, 21, 778.
[0187] Table 4 [Table 4]
[0188] The present disclosure should not be limited in scope by the embodiments disclosed in the examples, which are intended as single illustrations of individual aspects; any equivalents are within the scope of the present disclosure. Various modifications in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.
[0189] Various references are cited herein, such as patents, patent applications, and publications, the disclosures of which are incorporated herein by reference in their entireties.
Claims
1. Compounds of Formula I: Z-Gln-NH-L-Se-L 1 -R(I) or a pharma- ceutically acceptable salt thereof, Z is an antigen-binding domain; NH is the side chain NH of Gln, L and L 1 are the same or different and each is a linker; The compound or a pharma- ceutically acceptable salt thereof, wherein R is a payload.
2. 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein Z is an antibody or an antigen-binding fragment thereof.
3. 3. The compound of claim 1 or 2, or a pharma- ceutically acceptable salt thereof, wherein Z is an antibody.
4. The compound according to any one of claims 1 to 3, or a pharma- ceutically acceptable salt thereof, wherein Z is a N297Q mutant antibody.
5. 5. The compound of any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, wherein Z is an antibody having one or more engineered LLQG, LLQGG, LLQLLQG, LLQYQG, LLQGA, LLQGSG, SLLQG, LQG, LLQLQ, LLQLLQ, LLQGR, LLQYQGA, LQGG, LGQG, or LLQLLQGA sites.
6. 6. The compound of any one of claims 1 to 5, or a pharma- ceutically acceptable salt thereof, wherein Gln is Gln295 of the antibody, Gln297 of the N297Q mutant antibody, and / or Gln at an engineered LLQG, LLQGG, LLQLLQG, LLQYQG, LLQGA, LLQGSG, SLLQG, LQG, LLQLQ, LLQLLQ, LLQGR, LLQYQGA, LQGG, LGQG, or LLQLLQGA site.
7. 7. The compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt thereof, wherein Gln is Gln295 of the antibody.
8. 8. The compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof, wherein L is alkylene, alkenylene, cycloalkylene or arylene, or any combination thereof.
9. 9. The compound according to any one of claims 1 to 8, or a pharma- ceutically acceptable salt thereof, wherein L is alkylene.
10. 10. The compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt thereof, wherein L is ethylene.
11. L 1 11. The compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, wherein:
12. L 1 The compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof, wherein comprises valine-citrulline.
13. L 1 The compound according to any one of claims 1 to 12, or a pharma- ceutically acceptable salt thereof, wherein:
14. L 1 14. The compound of any one of claims 1 to 13, or a pharma- ceutically acceptable salt thereof, wherein: comprises a divalent p-aminobenzyloxy moiety.
15. L 1 or a pharma- ceutically acceptable salt thereof.
15. The compound of claim 1, wherein: 【Chemistry 1】
16. 16. The compound of any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof, wherein R is a therapeutic agent or an imaging agent.
17. 17. The compound of any one of claims 1 to 16, or a pharma- ceutically acceptable salt thereof, wherein R is a cytotoxic agent.
18. 18. The compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof, wherein R is MMAE.
19. L 1 The compound according to any one of claims 1 to 18, wherein -R is the following formula: or a pharma- ceutically acceptable salt thereof. 【Chemistry 2】
20. 20. The compound of any one of claims 1 to 19, or a pharma- ceutically acceptable salt thereof, wherein the drug to antibody ratio is 1 to 6.
21. 21. The compound of any one of claims 1 to 20, or a pharma- ceutically acceptable salt thereof, wherein the drug to antibody ratio is 2 to 4.
22. 22. The compound of any one of claims 1 to 21, or a pharma- ceutically acceptable salt thereof, wherein the drug to antibody ratio is 2.
23. A process for the synthesis of a compound according to any one of claims 1 to 22, or a pharma- ceutically acceptable salt thereof, comprising: (a) Z-Gln (H 2 reacting with N-L-Se)2 and transglutaminase; (b) reacting the product of step (a) with a reducing agent at a pH of 6 or less to obtain L 1 forming a reduced diselenide in the presence of -R, 1 contains a group that reacts with the reduced diselenide to form a covalent bond, thereby forming Z-Gln-NH-L-Se-L 1 forming -R.
24. 24. The process of claim 23, wherein the transglutaminase is a bacterial transglutaminase.
25. 25. The process of claim 23 or 24, wherein the reducing agent is tris(2-carboxyethyl)phosphine.
26. The process of any one of claims 23 to 25, wherein the group that reacts with the reduced diselenide is a maleimide group.
27. 27. The process of any one of claims 23 to 26, wherein, when Gln of Z-Gln is Q295 of N297 antibody, prior to step (a), Z-Gln is reacted with PNGaseF to deglycosylate N297.
28. 23. The compound according to any one of claims 1 to 22, or a pharma- ceutically acceptable salt thereof, wherein Z is an anti-HER2 antibody.
29. A pharmaceutical composition comprising a compound according to any one of claims 1 to 22 and 28, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.
30. 30. The pharmaceutical composition of claim 29 for treating or diagnosing a disease in a subject.
31. The pharmaceutical composition of claim 30 for treating a disease in a subject.
32. 32. The pharmaceutical composition of claim 30 or 31, wherein the disease is a HER2 positive tumor.
33. The pharmaceutical composition according to any one of claims 30 to 32, wherein the disease is HER2-positive breast cancer.
34. 34. The pharmaceutical composition of claim 33, wherein the HER2-positive breast cancer is metastatic.
35. A compound of formula II: 【Chemistry 3】 During the ceremony, Z is an antigen-binding domain; each 【Chemistry 4】 is the side chain of Gln, The compound, wherein L is a linker.
36. 36. The compound of claim 35 having the following formula IIa: 【Chemistry 5】
